Analyst Ratings

Upgrades, downgrades, and outlook changes from major analysts.

Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.

Articles

3,519 total articles

Stifel Affirms Buy on DexCom, Keeps $85 Price Target After Q4 Results

Stifel Affirms Buy on DexCom, Keeps $85 Price Target After Q4 Results

Stifel has reiterated a Buy rating on DexCom and maintained an $85.00 price target after the company’s fourth-quarter report, a level Stifel says is closely aligned with InvestingPro’s Fair Value assessment. The brokerage pointed to management’s upbeat commentary on sell-through trends that extended into early 2026, steady financial metrics and ups…

TD Cowen Reinstates Hold on XOMA After Generation Bio Deal; Analysts Weigh Royalty Portfolio Value

TD Cowen Reinstates Hold on XOMA After Generation Bio Deal; Analysts Weigh Royalty Portfolio Value

TD Cowen has resumed coverage of XOMA, Ltd. with a Hold rating after the company's acquisition of Generation Bio. The firm highlighted XOMA's sizable royalty portfolio and robust recent revenue growth, while noting it needs more confidence in the revenue prospects and asset valuation before moving to a more positive rating. XOMA's balance sheet str…